Systematic Early Use of Neuromuscular Blocking Agents in ARDS Patients
Launched by ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE · Mar 6, 2006
Trial Information
Current as of June 14, 2025
Completed
Keywords
ClinConnect Summary
The use of neuromuscular blocking agents (NMBA) in ARDS patients has not been extensively investigated. It has been recently demonstrated that a systematic 48-h infusion of NMBA is associated with a significant improvement in oxygenation as compared with a control group (Gainnier et al., Crit Care Med 2004). Moreover, a trend towards a reduction in the mortality rate has been observed. The aim of the study is to show a reduction of the mortality rate of ARDS patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ARDS with a PaO2 / FiO2 \< 150 with a PEEP \> 5 since less than 48 hrs
- • informed consent
- Exclusion Criteria:
- • NMBA allergy
- • Continuous administration of NMBA for ARDS prior inclusion
- • Age \< 18 yrs
- • SAPS II \> 70
- • Persistent air leak
About Assistance Publique Hopitaux De Marseille
Assistance Publique - Hôpitaux de Marseille (AP-HM) is a leading public healthcare institution in France, dedicated to providing high-quality medical care and advancing research in various clinical fields. As a prominent sponsor of clinical trials, AP-HM is committed to fostering innovation and improving patient outcomes through rigorous scientific investigation. With a multidisciplinary approach, the institution collaborates with a network of healthcare professionals, researchers, and academic partners to facilitate cutting-edge studies that address critical health challenges. AP-HM's dedication to ethical standards and patient safety underscores its role as a trusted leader in clinical research and healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aix En Provence, , France
Avignon, , France
Besancon, , France
Bordeaux, , France
Brest, , France
Clermont Ferrand, , France
Grenoble, , France
Lyon, , France
Marseille, , France
Marseille, , France
Marseille, , France
Marseille, , France
Montpellier, , France
Nice, , France
Nimes, , France
Nimes, , France
Paris, , France
Rennes, , France
Saint Etienne, , France
Toulon, , France
Patients applied
Trial Officials
Laurent Papazian, MD
Principal Investigator
Assistance Publique Hôpitaux de Marseille
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials